China NT Pharma Group Company Limited - Laporan Laba Rugi (TTM)

China NT Pharma Group Company Limited
HK ˙ SEHK ˙ KYG2114L1059
HK$ 1.28 ↑0.19 (17.43%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi China NT Pharma Group Company Limited menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2023
03-31
2023
06-30
2023
12-31
2024
03-31
2024
06-30
2024
12-31
2025
03-31
2025
06-30
Revenue 185 222 233 244 235 227 231 236 222 -57 -113 7 19 31 38 28 19
Change (%) 19.66 4.92 4.68 -3.46 -3.58 2.04 2.00 -6.12 -125.53 100.00 -106.51 162.44 61.90 21.29 -25.42 -34.09
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 75 87 90 94 87 81 84 87 85 -23 -46 13 26 33 21 9
Change (%) 15.78 3.94 3.79 -6.63 -7.10 3.73 3.59 -3.15 -126.98 100.00 100.00 27.78 -36.10 -56.49
% of Revenue 40.47 39.16 38.79 38.46 37.20 35.84 36.43 37.00 38.17 40.33 40.33 66.19 81.77 86.14 73.81 48.73
Gross Operating Profit 110 135 142 150 148 145 147 149 137 -34 -68 7 7 6 5 7 10
Change (%) 22.29 5.55 5.25 -1.47 -1.49 1.10 1.09 -7.86 -124.64 100.00 -110.91 -11.27 -12.70 -7.82 40.93 29.04
% of Revenue 59.53 60.84 61.21 61.54 62.80 64.16 63.57 63.00 61.83 59.67 59.67 100.00 33.81 18.23 13.86 26.19 51.27
SG&A 251 218 221 224 231 239 232 225 166 -6 -38 64 62 61 18 20 21
Change (%) -13.01 1.33 1.31 3.40 3.29 -2.83 -2.92 -26.40 -103.58 546.57 -265.43 -2.37 -2.42 -69.48 8.14 7.53
% of Revenue 135.20 98.29 94.93 91.87 98.39 105.40 100.36 95.52 74.88 10.51 33.97 863.07 321.08 193.52 48.70 70.62 115.21
R&D
Change (%)
% of Revenue
OpEx 315 295 302 309 314 320 317 313 251 -29 -84 64 75 86 51 41 31
Change (%) -6.48 2.36 2.31 1.86 1.82 -1.14 -1.15 -19.93 -111.48 192.25 -175.61 17.76 15.08 -40.59 -20.12 -25.19
% of Revenue 170.09 132.93 129.70 126.76 133.74 141.23 136.82 132.59 113.09 50.86 74.32 863.07 387.27 275.29 134.84 144.43 163.94
Operating Income -130 -73 -69 -65 -79 -93 -85 -77 -29 -28 -29 -56 -56 -55 -13 -13 -12
Change (%) -43.78 -5.38 -5.68 21.71 17.84 -8.87 -9.73 -62.30 -4.13 4.51 93.49 -1.20 -1.21 -75.89 -4.90 -5.16
% of Revenue -70.09 -32.93 -29.70 -26.76 -33.74 -41.23 -36.82 -32.59 -13.09 49.14 25.68 -763.07 -287.27 -175.29 -34.84 -44.43 -63.94
Interest Expense -97 -85 -88 -90 -89 -89 -90 -92 -82 -28 -18 -29 -25 -22 -32 -36 -40
Change (%) -11.84 2.85 2.77 -0.69 -0.69 1.67 1.65 -10.88 -65.15 -38.25 63.89 -12.29 -14.02 45.15 13.62 11.99
% of Revenue -52.10 -38.38 -37.63 -36.94 -38.00 -39.14 -39.00 -38.86 -36.89 50.34 15.54 -391.23 -130.75 -69.44 -83.10 -126.60 -215.11
Net Income -517 -358 -317 -277 -213 -150 -162 -175 -121 -55 -44 -144 -140 -137 -53 -62 -71
Change (%) -30.77 -11.26 -12.69 -23.01 -29.89 8.55 7.88 -31.04 -54.38 -20.53 227.99 -2.18 -2.23 -61.14 16.46 14.13
% of Revenue -278.77 -161.28 -136.41 -113.76 -90.72 -65.96 -70.17 -74.21 -54.51 97.39 38.70 -1,949.36 -726.55 -438.75 -140.56 -219.51 -380.13

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista